CRP Adverse Event Reporting & Safety Monitoring 3

Question 1

A research coordinator discovers a participant has experienced an unexpected serious adverse event. What is the FIRST priority action?

Accepted Answer

Ensure the participant receives appropriate medical care immediately

Answer

Complete and submit the MedWatch form to the FDA

Answer

Notify the sponsor's medical monitor before taking any other steps

Answer

Unblind the participant's treatment assignment to assess causality

Question 2

Emergency unblinding of a participant's treatment assignment is justified when:

Accepted Answer

Knowledge of the treatment is necessary for safe medical management of a serious adverse event

Answer

A participant requests to know their treatment assignment out of curiosity

Answer

A regulatory inspector requests the unblinded treatment codes

Answer

An investigator suspects the participant is non-compliant with study medication

Question 3

Which set of information is essential to document for every adverse event in a clinical trial?

Accepted Answer

Onset date, severity grade, relationship to study product, outcome, and action taken

Answer

Participant's insurance information and medical billing codes

Answer

Names of all study staff who witnessed or were present during the event

Answer

The participant's personal opinion about what caused the event

Question 4

In clinical trial safety monitoring, 'signal detection' refers to:

Accepted Answer

Identifying potential new safety concerns by analyzing patterns across accumulating adverse event data

Answer

Monitoring participant adherence using electronic device sensors

Answer

Detecting electronic data entry errors in case report forms

Answer

Monitoring site staff compliance with protocol-required procedures

Question 5

Pre-specified 'stopping rules' in a clinical trial protocol are designed to:

Accepted Answer

Halt or modify the trial if predefined safety thresholds are crossed

Answer

Terminate enrollment automatically once the target sample size is reached

Answer

Prevent participants from voluntarily withdrawing from the study

Answer

Stop all data collection activities during scheduled interim analyses

Question 6

Which agency must receive expedited adverse event reports for clinical investigations conducted under an Investigational New Drug (IND) application?

Accepted Answer

The U.S. Food and Drug Administration (FDA)

Answer

The Joint Commission on Accreditation of Healthcare Organizations

Answer

The Office for Human Research Protections (OHRP)

Answer

The National Institutes of Health (NIH) Office of Research Integrity

Question 7

After an IND Safety Report results in new safety information, a sponsor is typically required to update which document to reflect the new risk information?

Accepted Answer

The Investigator's Brochure (IB) with the new safety findings

Answer

The FDA Form 1572 for all investigators

Answer

The study's statistical analysis plan

Answer

The IRB's standard operating procedures